LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Avidity Biosciences Inc

Closed

SectorHealthcare

29.88 -0.17

Overview

Share price change

24h

Current

Min

28.97

Max

29.91

Key metrics

By Trading Economics

Income

-14M

-116M

Sales

-1.4M

1.6M

EPS

-0.9

Profit margin

-7,360.013

Employees

391

EBITDA

-10M

-131M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+118.04% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-357M

3.5B

Previous open

30.05

Previous close

29.88

News Sentiment

By Acuity

50%

50%

154 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Avidity Biosciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

22 Apr 2025, 09:30 UTC

Top News

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Peer Comparison

Price change

Avidity Biosciences Inc Forecast

Price Target

By TipRanks

118.04% upside

12 Months Forecast

Average 65.13 USD  118.04%

High 78 USD

Low 50 USD

Based on 15 Wall Street analysts offering 12 month price targets forAvidity Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

25.575 / 32.65Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

154 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.